TBX20 Regulates Angiogenesis Through the Prokineticin 2-Prokineticin Receptor 1 Pathway

Area of Science:

• Cardiovascular Biology
• Molecular Biology
• Developmental Biology

Background:

• Angiogenesis is vital for embryonic development and disease pathology.
• TBX20, a transcription factor, is essential for embryonic development and linked to congenital heart disease.
• The specific role of TBX20 in angiogenesis remained undescribed.

Purpose of the Study:

• To investigate the role of TBX20 in regulating angiogenesis.
• To identify downstream targets of TBX20 involved in angiogenesis.
• To explore the therapeutic potential of the TBX20-angiogenesis pathway.

Main Methods:

• Utilized loss- and gain-of-function approaches to study TBX20 in angiogenesis (in vitro and in vivo).
• Employed an angiogenesis gene array to identify TBX20's downstream targets.
• Validated findings in murine models and zebrafish, including gene knockdown and rescue experiments.

Main Results:

• TBX20 knockdown significantly decreased prokineticin 2 (PROK2) expression and impaired endothelial cell migration and in vitro angiogenesis.
• TBX20 deficiency reduced PROK2 expression and intraplug angiogenesis in a murine model.
• PROK2 administration enhanced angiogenesis and blood flow recovery; tbx20 and prok2/prokr1a disruption impaired angiogenesis in zebrafish, with rescue observed upon prok2/prokr1a overexpression.

Conclusions:

• Identified TBX20 as a novel regulator of angiogenesis through the PROK2-PROKR1 pathway.
• Revealed a TBX20-PROK2-PROKR1 signaling cascade that sustains vascular endothelial growth factor's proangiogenic effect.
• Proposed this pathway as a potential therapeutic target for angiogenesis-related diseases.